59 results on '"Banerjee, Susana"'
Search Results
2. Targeting NaPi2b in ovarian cancer
3. UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed dolaflexin antibody drug conjugate (ADC) in platinum-resistant ovarian cancer (585)
4. Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: A post-hoc analysis from the GARNET trial (210)
5. Physician behavior and perceptions around genetic biomarker test utilization for the management of newly diagnosed advanced ovarian cancer patients: US physician survey (223)
6. MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297)
7. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial
8. Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study
9. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial
10. Real-world outcomes in patients with advanced endometrial cancer: A retrospective cohort study of US electronic health records
11. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
12. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial
13. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial
14. PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
15. Comparative tolerability and dose modifications of poly(ADP-ribose) polymerase inhibitors in ovarian cancer: a retrospective cohort study of US healthcare claims data
16. Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1
17. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
18. Recent advancements of antiangiogenic combination therapies in ovarian cancer
19. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
20. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
21. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
22. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
23. Translational genomics of ovarian clear cell carcinoma
24. Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial
25. Avelumab Alone or in Combination with Chemotherapy vs Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): A Randomised, Open-Label, Phase 3 Study
26. Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians
27. First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion
28. An evaluation of self-perceived knowledge, attitudes and behaviours of UK oncologists about LGBTQ+ patients with cancer
29. Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change?
30. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
31. Analysis of tumour ecological balance reveals resource-dependent adaptive strategies of ovarian cancer
32. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper
33. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial
34. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial
35. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer
36. Global cancer control: responding to the growing burden, rising costs and inequalities in access
37. Report on the status of women occupying leadership roles in oncology
38. Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey
39. Bevacizumab in cervical cancer: a step forward for survival
40. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
41. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients
42. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials
43. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
44. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients
45. Improving outcomes for older women with gynaecological malignancies
46. ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016
47. Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases
48. Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
49. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
50. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.